133 related articles for article (PubMed ID: 16264349)
21. Pretargeted radioimmunotherapy (PRIT) using an antibody-streptavidin fusion protein in non-Hodgkin's lymphoma.
Weiden PL
Leuk Lymphoma; 2002 Oct; 43(10):1971-3. PubMed ID: 12481894
[TBL] [Abstract][Full Text] [Related]
22. Secondary acute myelogenous leukemia with MLL gene rearrangement following radioimmunotherapy (RAIT) for non-Hodgkin's lymphoma.
Nabhan C; Peterson LA; Kent SA; Tallman MS; Dewald G; Multani P; Gordon LI
Leuk Lymphoma; 2002 Nov; 43(11):2145-9. PubMed ID: 12539741
[TBL] [Abstract][Full Text] [Related]
23. Correlation of marrow dose estimates based on serial pretreatment radiopharmaceutical imaging and blood data with actual marrow toxicity in anti-CD20 yttrium-90 monoclonal antibody radioimmunotherapy of non-Hodgkin's B-cell lymphoma.
Erwin WD; Spies SM; Kelly ME; Rao P; Eckersberg-Rhodes TE; Nannapaneni M; Groch MW
Nucl Med Commun; 2001 Feb; 22(2):247-55. PubMed ID: 11258413
[TBL] [Abstract][Full Text] [Related]
24. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma.
Witzig TE; Gordon LI; Cabanillas F; Czuczman MS; Emmanouilides C; Joyce R; Pohlman BL; Bartlett NL; Wiseman GA; Padre N; Grillo-López AJ; Multani P; White CA
J Clin Oncol; 2002 May; 20(10):2453-63. PubMed ID: 12011122
[TBL] [Abstract][Full Text] [Related]
25. Cure of incurable lymphoma.
DeNardo GL; Sysko VV; DeNardo SJ
Int J Radiat Oncol Biol Phys; 2006; 66(2 Suppl):S46-56. PubMed ID: 16979440
[TBL] [Abstract][Full Text] [Related]
26. Radioimmunotherapy: a new treatment modality for B-cell non-Hodgkin's lymphoma.
Ghobrial I; Witzig T
Oncology (Williston Park); 2004 May; 18(5):623-30; discussion 633-4, 637-8, 640. PubMed ID: 15209190
[TBL] [Abstract][Full Text] [Related]
27. Rationale for consolidation to improve progression-free survival in patients with non-Hodgkin's lymphoma: a review of the evidence.
Morschhauser F; Dreyling M; Rohatiner A; Hagemeister F; Bischof Delaloye A
Oncologist; 2009; 14 Suppl 2():17-29. PubMed ID: 19819921
[TBL] [Abstract][Full Text] [Related]
28. Does health economics have an impact on non-Hodgkin's lymphoma patients' options?
Otte A
Nucl Med Commun; 2008 Aug; 29(8):748-9. PubMed ID: 18753830
[No Abstract] [Full Text] [Related]
29. Risk of histological transformation and therapy-related myelodysplasia/acute myeloid leukaemia in patients receiving radioimmunotherapy for follicular lymphoma.
Epperla N; Pham AQ; Burnette BL; Wiseman GA; Habermann TM; Macon WR; Ansell SM; Inwards DJ; Micallef IN; Johnston PB; Markovic SN; Porrata LF; Colgan JP; Ristow KM; Nowakowski GS; Witzig TE
Br J Haematol; 2017 Aug; 178(3):427-433. PubMed ID: 28466487
[TBL] [Abstract][Full Text] [Related]
30. A revolution in the treatment of non-Hodgkin's lymphoma.
DeNardo GL; O'Donnell RT; Oldham RK; DeNardo SJ
Cancer Biother Radiopharm; 1998 Aug; 13(4):213-23. PubMed ID: 10850358
[TBL] [Abstract][Full Text] [Related]
31. Radioimmunotherapy of non-Hodgkin's lymphoma: molecular targeting and novel agents.
Pauwels EK; Erba P
Drug News Perspect; 2007 Mar; 20(2):87-93. PubMed ID: 17440631
[TBL] [Abstract][Full Text] [Related]
32. Radioimmunotherapy as a therapeutic option for Non-Hodgkin's lymphoma.
Macklis RM
Semin Radiat Oncol; 2007 Jul; 17(3):176-83. PubMed ID: 17591564
[TBL] [Abstract][Full Text] [Related]
33. Biokinetics and dosimetry of 188Re-anti-CD20 in patients with non-Hodgkin's lymphoma: preliminary experience.
Torres-García E; Ferro-Flores G; Arteaga de Murphy C; Correa-González L; Pichardo-Romero PA
Arch Med Res; 2008 Jan; 39(1):100-9. PubMed ID: 18068002
[TBL] [Abstract][Full Text] [Related]
34. Follow-up results of a phase II study of ibritumomab tiuxetan radioimmunotherapy in patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma and mild thrombocytopenia.
Schilder R; Molina A; Bartlett N; Witzig T; Gordon L; Murray J; Spies S; Wang H; Wiseman G; White C
Cancer Biother Radiopharm; 2004 Aug; 19(4):478-81. PubMed ID: 15453962
[TBL] [Abstract][Full Text] [Related]
35. Radio-immunotherapy in low-grade non-Hodgkin's lymphoma.
Lemieux B; Coiffier B
Best Pract Res Clin Haematol; 2005 Mar; 18(1):81-95. PubMed ID: 15694186
[TBL] [Abstract][Full Text] [Related]
36. Radioimmunotherapy for non-Hodgkin's lymphoma.
Liebenguth P; Vogt Temple S
Semin Oncol Nurs; 2006 Nov; 22(4):257-66. PubMed ID: 17095402
[TBL] [Abstract][Full Text] [Related]
37. Non-myeloablative radioimmunotherapy for non-Hodgkin's lymphoma.
Schaefer-Cutillo J; Friedberg JW
Semin Hematol; 2008 Apr; 45(2):110-7. PubMed ID: 18381106
[TBL] [Abstract][Full Text] [Related]
38. 4. Antibody therapy for malignant lymphoma.
Tobinai K
Intern Med; 2007; 46(2):99-100. PubMed ID: 17220608
[TBL] [Abstract][Full Text] [Related]
39. Evaluation of response to fractionated radioimmunotherapy with 90Y-epratuzumab in non-Hodgkin's lymphoma by 18F-fluorodeoxyglucose positron emission tomography.
Bodet-Milin C; Kraeber-Bodéré F; Dupas B; Morschhauser F; Gastinne T; Le Gouill S; Campion L; Harousseau JL; Wegener WA; Goldenberg DM; Huglo D
Haematologica; 2008 Mar; 93(3):390-7. PubMed ID: 18268287
[TBL] [Abstract][Full Text] [Related]
40. Phase II trial of a transplantation regimen of yttrium-90 ibritumomab tiuxetan and high-dose chemotherapy in patients with non-Hodgkin's lymphoma.
Krishnan A; Nademanee A; Fung HC; Raubitschek AA; Molina A; Yamauchi D; Rodriguez R; Spielberger RT; Falk P; Palmer JM; Forman SJ
J Clin Oncol; 2008 Jan; 26(1):90-5. PubMed ID: 18025438
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]